Sepracor - Scientific Abstracts : XOPENEX(R) (levalbuterol)

1. Duru EA, Reno AL, Parks JL, Panettieri RA, Calhoun WJ, Ameredes BT. Modulation of ERK1/2 levels by enantiomers of albuterol in stimulated human airway smooth muscle cells. Am J Respir Crit Care Med 2009;179:A3914 (Abstract)

2. Gardner A, Purohit N, Torres F. beta2-adrenergic receptor-to-effector signaling: Differential effects of enantiomers of albuterol in human airway smooth muscle cells. Am J Respir Crit Care Med 2009;179:A1940 (Abstract)

3. Ibe BO, Raj JU. Regulation of platelet activating factor (PAF) metabolism in human bronchial smooth muscle cells (HBSMC) by albuterol isomers. Am J Respir Crit Care Med 2009;179:A2855 (Abstract)

4. Lundblad LKA, Rinaldi L, Norton RJ, Riesenfeld E, Poynter ME, Barone LM, Irvin CG. Albuterol amplifies airway hyperresponsiveness in an allergic asthma model. Am J Respir Crit Care Med 2009;179:A2414 (Abstract)

5. Schulman ES, Nishi H. Overnight incubation in (S)-albuterol exerts desensitizing effects on human lung mast cell interleukin-8 but not histamine release. Am J Respir Crit Care Med 2009;179:A3709 (Abstract)

6. Wittine L, Makani S, Cheng V, Takajima T, Finn PW. (R )-albuterol effect on T cell cytokine production. Am J Respir Crit Care Med 2009;179:A2776 (Abstract)

2008 XOPENEX (levalbuterol) Abstracts

1. Altman LC, Chan CK, Perigo S, Braun K, Johnson PY, Wight TN. Accumulation of the extracellular matrix (ECM) components, hyaluronan and versican in human lung cell cultures is modulated differently by R- and S- isomers of albuterol. JACI 2008;121(2):S121 (Abstract)

2. Duru EA, Parks JL, Panettieri RA, Calhoun WJ, Ameredes BT. (S)-albuterol associated modulation of stimulatory g-proten expression as a factor of serum stimulation in human airway smooth muscle cells. JACI 2008;121(2):S119 (Abstract)

3. Dhand R, Delgado C, DeClue A, Spinka C, Reinero C. Enantiospecific effects of regular, inhaled albuterol on airway inflammation in asthmatic cats. AJRCCM 2008;177(Supplement):A363 (Abstract)

4. Duru EA, Reno AL, Parks JL, Panettieri RA, Calhoun WJ, Ameredes BT. (S)-albuterol associated modulation of p38 activation as a function of serum stimulation in human airway smooth muscle cells. AJRCCM 2008;177(Supplement):A494 (Abstract)

5. Gardner A, Torres F, Tuiskula K, Kaur S. Effect of enantiomers of beta2-adrenergic receptor agonists on g-protein signaling in human airway smooth muscle cells. AJRCCM 2008;177(Supplement):A929 (Abstract)

6. Ibe BO, Abdallah MF, Raj JU. (S)-albuterol up-regulates platelet activating factor (PAF) receptor expression and PAF binding in human bronchial smooth muscle cells (HBSMC). AJRCCM 2008;177(Supplement):A66 (Abstract)

7. Lundblad LKA, Rinaldi L, Norton RJ, Riesenfeld E, Poynter ME, Barone LM, Irvin CG. Albuterol isomes amplify airway closure in a murine asthma model. AJRCCM 2008;177(Supplement):A943 (Abstract)

8. Poynter ME, Jones CC, Lundblad LK, Barone LM, Foster SR. Increased 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1) expression does not explain the NF-kappaB inhibitory effects of levalbuterol in murine airway epithelial cells. AJRCCM 2008;177(Supplement):A68 (Abstract)

9. Schulman ES, Nishi H. Albuterol stereoisomers exert differential effects on human lung mast cell mediator release. AJRCCM 2008;177(Supplement):A603 (Abstract)

10. Scuri M, Samsell L, Young EJ, Piedimonte G. Differential effects of (R ) an (S)-albuterol on virus-induced neural remodeling. AJRCCM 2008;177(Supplement):A191 (Abstract)

11. Walker JKL, Fischer B, Theriot BS, Brody AR. Mice chronically treated with (R,S)-albuterol, but not (R )-albuterol, demonstrate loss of bronchorelaxation. AJRCCM 2008;177(Supplement):A944 (Abstract)

12. Wang CLA, Huang R, Zhu L. Stereo-specific effects of albuterol on the migration of mouse tracheal cells. AJRCCM 2008;177(Supplement):A494 (Abstract)

13. Warner SM, Hackett TL, Knight DA. Asthmatic bronchial epithelial cells respond inappropriately to dexamethasone and albuterol in vitro. AJRCCM 2008;177(Supplement):A347 (Abstract)

14. Waterman JT, Jones JN, Adler KB. Albuterol-induced oxidant stress in primary cultures of normal human bronchial epithelial cells. AJRCCM 2008;177(Supplement):A469 (Abstract)

15. ZhuGe R, Bao R, Lifshitz LM, Tuft RA, Fogarty KE. Physiological role of Ca2+ sparks and their regulation by (S)- and (R)-albuterol in mouse airway smooth muscle. AJRCCM 2008;177(Supplement):A801 (Abstract)

16. Nie Z, Jacoby DB, Fryer AD. Effect of albuterol isomers on TNF-induced ICAM-1 and eotaxin expression in human parasympathetic neurons. FASEB J 2008;22:670.18 (Abstract)

17. Bauer A, Conners JJ, McVicar WK, Hanrahan JP, Stewart ES, Holt JT, Nagel MW, Mitchell JP, McGlynn P. Influence of valved holding chambers on emitted dose and particle size distribution of a metered dose inhaler using low-flow Marple-Miller impaction. In Abstracts of Respiratory Drug Delivery 2008:747-750 (Abstract)

18. Conners JJ, Bauer A, Holt JT, Stewart ES, Hanrahan JP, McVicar W, Baumgartner R, McGlynn P. Evaluation of the impact of pediatric breathing patterns on the emitted dose of a metered dose inhaler with valved holding chambers. In Abstracts of Respiratory Drug Delivery 2008:751-754 (Abstract)

19. Bielory L, Leonov A. Stereoconfiguration of antiallergic and immunologic drugs. Ann Allergy Asthma Immunol 2008;100(1):1-9.

20. Bonasia PJ, McVicar WK, Williams B, Ong S. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. Respiratory Care 2008;53(12):1716-1722.

2007 XOPENEX (levalbuterol) Abstracts

1. Andrews T, McGintee E, Tyler L, Mittal M, Chew A, Pawlowski N, Zorc J. Efficacy of high-dose continuous nebulized levalbuterol for pediatric status asthmaticus (Abstract). JACI 2007;(1):S244.

2. Duru EA, Parks JL, Calhoun WJ, Ameredes BT. Modulation of effects of albuterol enantiomers on IL-6 release in human airway smooth muscle cells as a function of cellstimulation (Abstract). JACI 2007;(1):S296.

3. McVicar WK, Bonasia P, Ong S. Compatability of levalbuteol inhalation solution mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium (Abstract). JACI 2007;(1):S1.

4. McVicar WK, Korenblat PE, Pleskow WW, Rees Wc, Parsey M, Tripp K, Baumgartner RA. Cumulative dose tolerability study of levalbuterol HFA and racemic albuterol HFA in patients with asthma (Abstract). Presented as a poster at the Southwest Allergy Fourm, January 17 - 21, 2007 in Puerta Vallarta, Mexico.

5. Pearlman DS, Rees W, Huang H, Schaefer K, Andrews W. An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm (Abstract). Presented as a poster at Western Society of Allergy, Asthma, & Immunology 2007 in Maui, Hawaii.

2006 XOPENEX (levalbuterol) Abstracts

1. Agrawal DK, Cheng G, Kelbe PW, Bakale R. Class-specific effect of the enantiomers of b2-agonists on the activation of nuclear factor kb in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A77.

2. Agrawal DK, Kim MJ, Kelbe PW, Bakale R. Class-specificity of the binding of [3H](S)-albuterol in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A467.

3. Agrawal DK, Cheng G, Kelbe P. Masking of corticosteroid-induced inhibition of NF-kb activation by (S)-albuterol in human airway smooth muscle cells and human blood lymphocytes (Abstract). JACI 2006, 117[2], S140.

4. Andrews T, McGintee E, Tyler L, Mittal M, Pawlowski NA, Zorc JJ. Safety of high-dose continuous levalbuterol (Abstract). JACI 2006, 117[2], S196.

5. Berger WE, Milgrom H, Kim K, Tripp K, Maier G, Baumgartner R. Levalbuterol HFA MDI for treatment of pediatric asthma: a double-blind, randomized, placebo- and active- controlled trial (Abstract). Annual Meeting of the Western Society of Allergy, Asthma, & Immunology. 2006.

6. Cheng G, Kelbe PW, Agrawal DK. Induction of nuclear factor kb activity and masking of the beneficial effect of corticosteroid by (s)-albuterol in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A77.

7. Cleary JC, Karmazyn Y, Mogayzel PJ, Laube BL. Chronic administration of levalbuterol or racemic albuterol does not enhance mucociliary clearance in healthy subjects (Abstract). Proceedings of the American Thoracic Society 2006;3:A78.

8. Finn PW, Amirifeli S, He H, Campo M, Ferrada M, Barone L, Perkins D. Albuterol in an allergic murine model (Abstract). Proceedings of the American Thoracic Society 2006;3:A346.

9. Frieri M, Capetandes A. (R)-, but not (S)-, enantiomers of beta2 agonists inhibit IL-8 secretion by rsv antigen-stimulated confluent human alveolar epithelial cells (cA549) (Abstract). JACI 117[2], S318. 2006.

10. Mendes ES, Campos MA, Wanner A. A novel mechanism of glucocorticoid-adrenergic interaction in the regulation of airway blood flow (Abstract). Proceedings of the American Thoracic Society 2006;3:A688.

11. Milgrom H, Berger WE, Kim K, Tripp K, Maier G, Baumgartner R. Levalbuterol HFA MDI for treatment of pediatric asthma: a double-blind, randomized, placebo- and active- controlled trial (Abstract). Annual Meeting of Southwest Allergy Forum . 2006.

12. Morris GF, Johnson AR, Perry LA, Brody AR. Activation of the human proliferating cell nuclear antigen (PCNA) promoter in vivo and in cell culture by stereoisomers of albuterol (Abstract). Proceedings of the American Thoracic Society 2006;3:A697.

13. Puglisi G, Capetandes A, Frieri M. 10-6M (RR)-formoterol, but not (SS)-formotrol or (S)/(R)-albuterol, inhibits rantes secretion by rsv antigen- stimulated confluent human alveolar epithelial cells (cA549) (Abstract). JACI 117[2], S155. 2006.

14. Schulman ES, Nishi H, Pelleg A. Differential effects of albuterol stereoisomers on human lung mast cell mediator release (Abstract). Proceedings of the American Thoracic Society 2006;3:A589.

2005 XOPENEX (levalbuterol) Abstracts

1. Chorley BN, Adler KB. β2-adrenergic receptor activation with (r)-albuterol attenuates granulocyte macrophage colony stimulating factor (GM-CSF) expression via an iNOS-mediated pathway in human brochial epithelial cells in vitro. Proceedings of the American Thoracic Society 2005; 2:A757 (Abstract).

2. Codispoti C, Calhoun WJ, Ameredes BT. Eotaxin release from human airway smooth muscle cells treated with albuterol enantiomers. JACI 2005, 115(2):S48 (Abstract).

3. Donohue JF, Parsey M, Andrews C, D'Urzo T, Sharma S, Schaefer K, Claus R, Baumgartner R. Levalbuterol in the treatment of patients with Chronic Obstructive Pulmonary disease. CHEST 2005;128(4):260S. (Abstract).

4. Emerman C, Nowak R, Hanania N, Koester J, Claus R, Anderson A, Roach J, McVicar W, Hanrahan J. Fev1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Aspen Allergy Conference, July 26 - 30, 2005, Aspen, CO (Abstract).

5. Frieri M, Capetandes A. (S)-albuterol increases CysLT1R expression and VEGF mRNA by normal human lung fibroblasts (NHLF). JACI 2005, 115(2):S14 (Abstract).

6. Frieri M, Capetandes A. Effect of (s)-albuterol vs (r)-albuterol on vascular endothelial growth factor, basic fibroblast growth factor and fibronectin secretion from normal human fibroblasts and myofibroblasts. Ann Allergy Asthma Immunol 2005; 1:185 (Abstract).

7. Hanania N, Emerman C, Nowak R, Claus R, Varga J, Andrews W, McVicar W, Hanrahan JP. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Annual Meeting of the Southwestern Allergy Forum 2005, Puerta Vallarta, Mexico (Abstract).

8. Hanania N, Emerman C, Nowak R, Claus R, Snider ME, Varga J, Andrews W, McVicar W, Hanrahan JP. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Annual Meeting of the Western Society of Allergy, Asthma, & Immunology 2005, Hawaii (Abstract).

9. Ozminkowski RJ, Long SR, Wang S, Barry N, Schaefer K. Healthcare utilization for elderly Medicaid patients treated with nebulized levalbuterol (LEV) or racemic albuterol (RAC). Proceedings of the American Thoracic Society 2005; 2:A925 (Abstract).

10. Perry A, Persinger R, Schwartz Y, Chang M, Wu R. (R)- and (S)-albuterol exhibit differential effects on mucociliary transport and mucin secretion. Presented at the Gordon Conference on Cilia, Mucus & Mucociliary Interactions, February 27 - March 4, 2005, Buellton, CA (Abstract).

11. Pikarsky RS, Acevedo RA, Farrell T, Fascia W. Breakthrough treatment rates during a conversion to levalbuterol, tiotropium and breath actuated nebulizers. CHEST 2005; 128(4):259S. (Abstract).

12. Pikarsky RS, Acevedo RA, Farrell T, Fascia W. Economic impact resulting from a conversion to levalbuterol every six to eight hours. CHEST 2005;128(4):259S. (Abstract).

13. Puglisi G, Horne N, Huang YC, Frieri M. Transforming growth factor beta 1 (TGF-β1) production and expression from ragweed stimulated human alveolar epithelial cells (A549): modulation by budesonide, formoterol, and levalbuterol. Ann Allergy Asthma Immunol 2005; 1:165 (Abstract).

14. Raissy HH, Harkins M, Esparham A, Kelly HW. A double-blind, placebo-controlled crossover comparison of the dose-response to levalbuterol for reversing methacholine-induced bronchoconstriction with and without pretreatment with (s)-albuterol. Proceedings of the American Thoracic Society 2005; 2:A356. (Abstract).

15. Rance K, Trent C. Improved asthma outcomes achieved through a synergistic relationship between education and pharmacology in a high-risk population. Presented at the National Association of Pediatric Nurse Practitioners Annual Meeting, March 31 - April 3, 2005, Phoenix, AZ (Poster).

16. Nie Z, Jacoby DB, Fryer AD. Effect of albuterol isomers on TNF-α induced ICAM-1 and eotaxin expression in human parasympathetic neurons. FASEB J 2008;22:670.18 (Abstract)

19. Bielory L, Leonov A. Stereoconfiguration of antiallergic and immunologic drugs. Ann Allergy Asthma Immunol 2008;100(1):1-9.

21. Cleary JC, Karmazyn Y, Mogayzel PJ, Laube BL. Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects. Pulm Pharm Ther 2008;21(1):105-111.

22. Delmotte P, Sanderson MJ. Effects of albuterol isomers on the contraction and Ca2+ signaling of small airways in mouse lung slices. Am J Respir Cell Mol Biol 2008;38:524-531.

23. Donohue JF, Hanania NA, Ciubotaru RL, Noe L, Pasta DJ, Schaefer K, Claus R, Andrews WT, Roach J. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clinical Therapeutics 2008;30(Theme Issue):989-1002.

24. Ferrada MA, Gordon EL, Jen KY, He HZ, Lu X, Barone LM, Amirifeli S, Perkins DL, Finn PW. (R)-albuterol decreases allergic responses: role of activated T cells. Respiratory Research 2008;9:3 doi:10.1186/1465-9921-9-3.

25. Frieri M, Capetandes A. The effect of enantiomers of beta-agonists on myofibroblast-derived vascular endothelial growth factor and other matrix components in the presence of dust-mite extract. Allergy Asthma Proc 2008;29(2):182-188.

26. Ibe BO, Abdallah MF, Raj JU. Mechanisms by which s-albuterol induces human bronchial smooth muscle cell proliferation. International Archives of Allergy and Immunolgy 2008;146(4):321-333.

27. Tripp K, McVicar WK, Nair P, Corren J, Pleskow WW, Goodwin E, Baumgartner RA, Hanrahan JP. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. JACI 2008;122:544-549.

28. Yamreudeewong W, Teixeira MG, Mayer GE. Stability of levalbuterol in a mixture of levalbuterol and ipratropium nebulizer solution. Hospital Pharmacy 2008;43(4):303-306.